HER2+ metastatic breast cancer

EU Approves Enhertu Plus Pertuzumab for First-Line HER2-Positive Metastatic Breast Cancer

Post author:Austin Newman
Post published:September 4, 2026
Post category:Metastatic Breast Cancer

As reported on Business Wire, the European Commission has approved trastuzumab deruxtecan (Enhertu) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More